Orthocell’s CEO and Managing Director Paul Anderson has featured on Beyond The Medicine Cabinet podcast to talk about regenerative nerve repair, and how Orthocell’s Remplir™ collagen nerve wrap is revolutionising surgery for patients with peripheral nerve injuries.
VIDEO | Proactive Investors – September 2022
Orthocell’s Paul Anderson spoke with Andrew Scott at Proactive Investors to discuss to discuss the announcement that the Company had secured Device Technologies as the exclusive distribution partner for Remplirâ„¢ in the Australian marketplace.Â
Orthocell appoints Device Technologies as distributor of its nerve repair device in Aus, NZ
Orthocell’s distribution deal with Device Technologies has been featured in The West Australian, in this news article by business reporter Cheyanne Enciso.
Appointment of exclusive distributor of Remplirâ„¢ in Australia
Orthocell has appointed Device Technologies as the exclusive distributor of Remplirâ„¢ for peripheral nerve repair in Australia.Â
VIDEO | Proactive Investors – July 2022
Orthocell’s Paul Anderson spoke with Alisha Newell at Proactive Investors to discuss the Company’s strong position following the recently executed global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc for $OCC’s Striate+™ dental membrane.
Dr Boreham’s Crucible | July 2022
Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist, Tim Boreham.Â
VIDEO | ShareCafe ‘Hidden Gems’ Webinar – July 2022
Orthocell CEO and Managing Director, Paul Anderson, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.
Striate+â„¢ global exclusive license and manufacturing agreement with BioHorizons
Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+â„¢, with BioHorizons Implant Systems Inc – one of the largest dental implant companies in the world.Â
Remplir™ Channel 7 News feature
Clinical trial participant Damian Hall was featured in a national news story by Channel 7 News Reporter, Alison Fan, to discuss his path to continued mobility following a nerve repair procedure with Remplirâ„¢.
Quarterly Report | Period To 31 March 2022
Orthocell has today published its Quarterly Report for the period ended 31 March 2022.
Standout achievements for this Quarter include:
- Remplirâ„¢ nerve repair device receives Australian regulatory approval for introduction into the Australian nerve repair and regeneration market
- Application for inclusion of Remplirâ„¢ on the Prostheses List on track for submission in Q2 CY2022
- Final Remplirâ„¢ 24 month results of all patients in the nerve regeneration study on track for Q2 CY2022
- SignificantStriate+â„¢ US market entry progress with sale of over 1,500 Striate+â„¢ units achieved, and commencement of facility upgrade to enable scale up Striate+â„¢ manufacturing capacity to >100,000 units per year
- Striate+â„¢ distributor discussions progressed and the Company is in advanced discussions to engage its first US distributor and establish Striate+â„¢ as the premium dental membrane
- The final data from the OrthoATIâ„¢ Phase 2a study on track for Q2 CY2022